Ossiam Catalent, Inc. Transaction History

Ossiam

$5.1 Billion
Q3 2024

A detailed history of Ossiam transactions in Catalent, Inc. stock. As of the latest transaction made, Ossiam holds 295,811 shares of CTLT stock, worth $18.8 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares

295,811

Previous 10,935 2605.18%

Holding current value

$18.8 Million

Previous $614,000 2818.08%

% of portfolio

0.35%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$56.16 - $60.96 $16 Million - $17.4 Million	284,876 Added 2605.18%	295,811 $17.9 Million
Q2 2024 Aug 13, 2024	BUY	$53.58 - $57.02 $14,305 - $15,224	267 Added 2.5%	10,935 $614,000
Q1 2024 May 13, 2024	BUY	$42.56 - $59.82 $39,538 - $55,572	929 Added 9.54%	10,668 $602,000
Q3 2023 Nov 14, 2023	SELL	$44.2 - $50.2 $11.8 Million - $13.4 Million	-266,281 Reduced 96.47%	9,739 $443,000
Q2 2023 Aug 11, 2023	BUY	$31.86 - $67.26 $8.61 Million - $18.2 Million	270,253 Added 4686.2%	276,020 $12 Million
Q1 2023 May 12, 2023	BUY	$45.44 - $74.26 $185,713 - $303,500	4,087 Added 243.27%	5,767 $378,000
Q3 2022 Nov 14, 2022	BUY	$72.36 - $113.1 $121,564 - $190,008	1,680 New	1,680 $122,000
Q2 2022 Aug 12, 2022	SELL	$87.2 - $114.05 $365,019 - $477,413	-4,186 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$94.19 - $124.49 $1.04 Million - $1.38 Million	-11,046 Reduced 72.52%	4,186 $464,000
Q4 2021 Feb 14, 2022	BUY	$119.57 - $139.07 $1.14 Million - $1.32 Million	9,499 Added 165.69%	15,232 $1.95 Million
Q3 2021 Nov 12, 2021	SELL	$109.17 - $142.35 $368,121 - $480,004	-3,372 Reduced 37.03%	5,733 $763,000
Q2 2021 Aug 13, 2021	BUY	$100.34 - $115.69 $913,595 - $1.05 Million	9,105 New	9,105 $1.09 Million

Others Institutions Holding CTLT

# of Institutions

515

Shares Held

149M

Call Options Held

575K

Put Options Held

2.03M

View Full List

About Catalent, Inc.

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $11.4B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

More about CTLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ossiam, based on Form 13F filings with the SEC.

News

Stay updated on Ossiam with notifications on news.

Account